Organ Specific Damage Assessment Biomarker Assays

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 2R44ES012277-02
Agency Tracking Number: ES012277
Amount: $0.00
Phase: Phase I
Program: SBIR
Awards Year: 2003
Solicitation Year: N/A
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
OXFORD BIOMEDICAL RESEARCH, INC.
OXFORD BIOMEDICAL RESEARCH, INC., BOX 522, 4600 GARDNER RD, METAMORA, MI, 48455
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 THOMAS BROWN
 (248) 852-8815
 TBROWN@OXFORDBIOMED.COM
Business Contact
 DENIS CALLEWAERT
Phone: (248) 852-8815
Email: CALLEWAE@OXFORDBIOMED.COM
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): Biomarkers that accurately reflect acute and/or past exposure to harmful agents are crucial in any study aiming to reduce the incidence of diseases resulting from environmental chemicals or other exposures. The biomarkers evaluated to date in biological fluids with relatively non-invasive access generally lack organ specificity and are not sensitive enough to detect mild damage and/or damage that occurred in the past In Phase I we employed a novel approach to identify unique biomarkers of acute exposure to toxicants in two rodent models. Following administration of toxicants in rat liver and lung damage models, we immunopurifed oxidized organ specific proteins from serum using mini prep affinity resins prepared with antibodies against three oxidized amino acids, chlorotyrosine, nitrotyrosine and methanionine sulfoxide. We then identified those proteins that were liver or lung specific by the proteomics approach of 2D gel separation, computerized and robotic spot picking, in-gel digests and MALDI/MS analysis. We succeeded in identifying several such damage biomarkers in serum derived from both lung and liver after administration of ozone and CCl4. Having demonstrated proof of concept in Phase I, in Phase II we propose to expand our studies to multiple organ systems, develop and validate highly specific sandwich immunoassays for oxidized protein biomarkers specific for various tissues, demonstrate proof of diagnostic concept and develop a prototype miniarray consisting of multiple organ specific oxidized protein biomarker ELISAs. Our long-term objective is to develop miniarrays of rat and human, organ-specific, damage assessment biomarkers. In a broad sense these arrays can serve the toxicology industry for both environmental agent exposure assessment and for drug development toxicology studies in animals and humans. In addition, they could be useful in clinical settings for the identification and monitoring of diseases in which diagnosis is difficult or equivocal.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government